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Low-dose radiotherapy (LD-RT) has been used for several
benign diseases, including arthrodegenerative and inflamma-
tory pathologies. Despite its effectiveness in clinical practice,
little is still known about the mechanisms through which
LD-RT modulates the various phases of the inflammatory
response and about the optimal dose fractionation.
The objective is to summarize current knowledge on
the radiobiological mechanisms underlying the anti-
inflammatory effects of LD-RT in in vitro experiments, in
in vivo experimental models and in clinical studies, and to
provide recommendations on the most effective and safe
LD-RT treatment schedules.
1. Introduction
Radiotherapy (RT) is recognized as one of the main modal-
ities in the treatment of cancer. However, the use of RT to
treat some benign diseases has received considerably less
attention. The term “benign disease” in the radiotherapeutic
context encompasses a series of non-neoplastic pathologies
that have negative effects on quality of life. High-dose RT
induces the production of pro-inflammatory cytokines, lead-
ing to an inflammatory response in the irradiated tissues.
Paradoxically, RT administered at low doses has the ability
to modulate an on-going inflammatory response, produc-
ing an anti-inflammatory effect. The efficacy of LD-RT has
been demonstrated in the treatment of degenerative bone
and inflammatory diseases, such as osteoarthritis, humeral
epicondylitis, scapular-humeral periarthritis, or heel spurs.
Despite the known efficacy of LD-RT, irradiation regimens
are still not well established. Some protocols recommend
doses between 0.3 and 1.5 Gy over 4–5 sessions per week for
acute conditions (up to a total dose of 3–5 Gy) or 1–3 ses-
sions per week for chronic conditions (up to a total dose of
12 Gy). Similarly, the radiobiological mechanisms involved in
the anti-inflammatory action of LD-RT have not been com-
pletely elucidated. 1–6
2. Role of RT in benign diseases. Accepted
indications and clinical studies
The use of RT in benign pathology is not universal. Countries
such as Germany use it extensively, whereas the use of RT for
this purpose is anecdotal in other countries. The German Work
Group on RT and Benign Diseases published a consensus on
possible indications. Low doses should be used for the acute
and chronic inflammatory diseases and for painful acute and
chronic degenerative joint disease.
The efficacy of LD-RT for inflammatory/degenerative joint
disorders has been confirmed in various clinical studies. In
painful knee osteoarthritis, the administration of 3–6 Gy at a
rate of 0.35–1 Gy/session led to 60–70% improvement in pain.
3. Anti-inflammatory mechanisms of
LD-RT
LD-RT modulates the function of a variety of inflamma-
tory cells, including endothelial cells, polymorphonuclear
leukocytes, and macrophages. Various hypotheses have
been offered to explain the mechanisms of LD-RT, such
as a decreased adhesion of polymorphonuclear cells to
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endothelial cells, induction of apoptosis in the cells that
comprise the inflammatory infiltrate, decreased expression
of adhesion molecules (P-, L-, E-selectins, ICAM-1, VCAM-1),
decreased iNOS that results in a decrease in NO and ROS,
increased activation of Nuclear Factor-Kappa B (NF-kB) and
increased expression of anti-inflammatory cytokines (IL-10,
TGF-1).
The majority of in vitro studies have characterized the pos-
sible mechanisms that explain the anti-inflammatory effects
of LD-RT, whereas in vivo studies have observed improvements
in clinical parameters in diverse experimental models.1–6
4. Conclusions
RT administered at high doses induces production of pro-
inflammatory cytokines in immune cells and endothelial
cells. Paradoxically, LD-RT acts upon cells that participate in
the inflammatory response, producing an anti-inflammatory
effect. This anti-inflammatory effect has been demonstrated
in in vitro studies, in experimental in vivo studies and in clinical
studies. The efficacy of LD-RT has been demonstrated exper-
imentally by lowering clinical inflammatory parameters and
improving histological markers in various models of arthritis,
with doses ranging from 0.5 to 1.5 Gy. In vitro studies suggest
that LD-RT has a potent anti-inflammatory effect, inhibiting
leukocyte–endothelium interactions at doses under 0.7 Gy. In
contrast, inflammatory and degenerative bone diseases in
humans are treated with doses ranging from 0.3 to 1.5 Gy.
Thus, using lower doses in the range 0.1–0.3 Gy could maxi-
mize anti-inflammatory effects and minimize toxicity. With
respect to mechanisms underlying the anti-inflammatory
effect, potential mediators include a decrease in selectins,
a decrease in NO production, an increase in apoptosis, an
increase in NF-kB, and an increase in the expression of anti-
inflammatory cytokines such as TGF-1. The effect of LD-RT
over time has also been studied to establish an optimal radio-
therapeutic treatment regimen; the effect is maintained up to
48 h after LD-RT and lost at 72 h. Therefore, clinical practice
would likely require LD-RT treatments with fractions every
48–72 h. Properly designed and powered clinical studies are
necessary to determine the most efficacious treatment dose
and schedules, and to establish the role of LD-RT in the ther-
apeutic algorithm of inflammatory conditions.
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